Best Weight Loss Supplements in 2026 — Ranked & Reviewed
We independently evaluated and scored the top weight loss supplements of 2026 based on value, effectiveness, user experience, and more.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 5
Detailed Reviews
Buoy
Best for: GLP-1-companion electrolyte supplement
Buoy (justaddbuoy.com) is a liquid electrolyte drop with 87+ trace minerals, vitamins, and antioxidants from an ocean-electrolyte and whole-food base. Buoy markets itself as a general hydration and electrolyte product, NOT as a weight-loss or GLP-1-specific product — we list it here because electrolyte loss is a documented side effect of rapid GLP-1-mediated weight loss, but readers should know the GLP-1 framing is editorial, not the brand's own primary positioning.
Score Breakdown
Pros
- ✓Liquid format mixes into any beverage — easier compliance than electrolyte powders
- ✓Sugar-free / no artificial sweeteners (per brand positioning)
- ✓Useful adjunct for GLP-1 patients who experience electrolyte loss from reduced appetite and rapid weight loss
Cons
- ✗Stub entry — exact pricing, ingredient panel per serving, and clinical positioning need a YMYL verification pass
- ✗Confidence is LOW until that pass is done
- ✗Not a substitute for prescription electrolyte management in clinically significant cases
Gruns Greens
Verified partnerBest for: daily-multivitamin gummy as a GLP-1 nutrition adjunct
Gruns is a daily greens gummy positioned as a more palatable alternative to powdered greens and traditional multivitamins. Marketed as a nutrition-density tool that pairs with weight-loss diets and GLP-1 therapy to maintain micronutrient intake when overall food intake drops.
Score Breakdown
Pros
- ✓Gummy format is dramatically more compliance-friendly than powdered greens or capsule multivitamins
- ✓Useful for GLP-1 patients who experience reduced appetite and need a low-volume way to maintain micronutrient intake
- ✓Brand-recognition lever — Gruns has run high-visibility marketing campaigns through 2024-2025
Cons
- ✗Stub entry — exact ingredient panel, third-party lab testing, FDA adverse actions, and pricing tiers need a YMYL verification pass
- ✗Confidence is LOW until that pass is done
- ✗Not a substitute for clinical nutrition management — greens supplements have weak evidence relative to whole-food vegetable intake
IM8 Health
Best for: all-in-one daily greens-and-vitamin blend with independent third-party (NSF) quality testing
IM8 Health is a daily health drink and supplement system co-founded by David Beckham and Prenetics CEO Danny Yeung, positioning itself as an all-in-one greens, prebiotic, probiotic, vitamin, mineral, and adaptogen blend. Marketed for energy, gut health, longevity, and metabolic support. Distributed in the US by Prenetics Global Limited.
Score Breakdown
Pros
- ✓All-in-one daily blend reduces stack complexity vs. taking 5-10 separate supplements
- ✓NSF Certified for Sport — independent third-party testing for banned-substance contamination and label accuracy
- ✓Scientific advisory board includes Dr. James L. Green (former NASA Chief Scientist) and Dr. Dawn Mussallem (Mayo Clinic)
Cons
- ✗Newer brand (US launched December 2024) — long-term outcome data does not exist yet
- ✗Not a weight-loss product — marketed as general wellness/longevity, not a metabolic-support therapy
- ✗Not a substitute for whole-food nutrition or clinical supplementation
- ✗Exact ingredient doses per serving and full ingredient panel still need to be pulled off-site before featuring
fatty15
Best for: single-ingredient C15:0 longevity supplement
fatty15 is a daily C15:0 (pentadecanoic acid) supplement marketed for cellular longevity, metabolic health, and inflammation reduction. C15:0 is an odd-chain saturated fatty acid that the company's published research positions as the first essential fatty acid to be discovered in 90+ years, with claimed effects on cell membrane stability and mitochondrial function.
Score Breakdown
Pros
- ✓Single-ingredient C15:0 supplement with a clear cell-membrane mechanism and published research behind it
- ✓Strong brand recognition from high-profile longevity marketing
- ✓C15:0 is hard to get from diet alone (mainly dairy fat), giving supplementation a defensible rationale
Cons
- ✗Pricing, ingredient panel, third-party lab testing, and longevity claims still need independent verification
- ✗Whether C15:0 should be classified as an essential fatty acid is the company's own positioning, not settled consensus
- ✗Not a weight-loss product — listed for longevity/metabolic-health overlap, not because it causes weight loss
Enhanced
Best for: not a GLP-1 provider — listed for completeness only
Enhanced is the consumer brand tied to the Enhanced Games athletic competition — not a GLP-1 weight-loss telehealth provider. Its shop sells two retail dietary supplements, LONGER+ (longevity) and STRONGER+ (performance), each $200 regular or $125 on sale, plus branded apparel. There are no GLP-1, testosterone, or peptide products and no telehealth pathway, so it is listed here only as an out-of-scope reference.
Score Breakdown
Pros
- ✓Public pricing on retail supplements
- ✓Clear FDA dietary-supplement disclaimer
Cons
- ✗Not a GLP-1 weight-loss telehealth provider — outside our core directory scope
- ✗No prescription medications, peptides, or compounded drugs offered
- ✗Affiliated with the controversial Enhanced Games competition
- ✗No LegitScript seal and no licensed-provider network disclosed
- ✗Active ingredients in its LONGER+ / STRONGER+ products not disclosed
Related Rankings
Frequently Asked Questions
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.